Omicia Finds $23M For Precision Medicine
Oakland-based Omicia, which is developing clinical genome interpretation and reporting software for the personalized medicine market, said this morning that it has raised $23M in a Series B funding. The funding came from UPMC Enterprises, Roche Venture Fund, LDV Partners, Ping An Ventures, an un-named, "large genomics investor", along with ARTIS Ventures, Acadia Woods Partners and Buchanan Investments. Omicia is led by CEO Matt Tindall.
posted on Wednesday, June 8, 2016 (Link to more information)
Related companies:
Omicia
Related stories:
> Omicia Buys Spiral Genetics
> Syapse Gets $30M For Precision Oncology Efforts
> SurveyMonkey Acquires Precision Polling
> Hua Medicine Gets $50M
> DroneDeploy Finds $2M For Drones On The Farm
silicontap.com Home